Would you give additional chemotherapy to women with stage III HER2+ breast cancer who have a grossly suboptimal response to neoadjuvant TCHP x6?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA

Or would you proceed with standard-of-care adjuvant approach for high risk patients?

Answer from: Medical Oncologist at Academic Institution

It really would depend on the hormone receptor status of the patient. If a patient was ER positive, one may not expect a pCR from TCHP, and they may benefit from Neratinib extended therapy based on the ExteNET trial. The HR was 0.6 for IDFS for the patients that had tumors that were hormone receptor...

Comments

Medical Oncologist at NYU Winthrop Hospital
Katherine trial recommends Kadcyla after residual...

Related Questions